Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01293591
Other study ID # Garlic Study 2010
Secondary ID
Status Completed
Phase N/A
First received February 8, 2011
Last updated June 1, 2017
Start date July 2010
Est. completion date August 2010

Study information

Verified date February 2011
Source USDA Beltsville Human Nutrition Research Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is being done to study the healthful benefits of eating garlic. Previous studies suggest that garlic may help prevent cancer. The investigators are recruiting healthy volunteers to participate in a study to determine the ways in which eating garlic may reduce cancer risk.


Description:

A crossover design will be utilized with each participant completing each treatment phase; participants will be randomly assigned to a sequence of dietary treatments. There will be a 17-day washout period in between diet periods. Participants will consume a garlic-free diet for the first 10 days of each diet period. The dietary treatments will be administered on day 11 of each diet period. Dietary treatments will be incorporated into food as follows: 1) 5 g (0.175 oz.) of garlic mixed with 15 g margarine on top of 270 kcal white bread, served as breakfast, or 2) 15 g margarine on top of 270 kcal white bread, served as breakfast.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date August 2010
Est. primary completion date August 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria:

- Age 40-80 years

Exclusion Criteria:

- Younger than 40 years old or older than 80 years old

- Use of blood-thinning medications such as Coumadin (warfarin), Dicumarol (dicumarol), or Miradon (anisinidione)

- Presence of kidney disease, liver disease, gout, certain cancers, thyroid disease, gastrointestinal, other metabolic diseases or malabsorption syndromes.

- Have been pregnant during the previous 12 months, are currently pregnant or lactating, or plan to become pregnant during the study

- Follicle stimulating hormone levels above 35 mIU/mL serum

- Type 2 diabetes requiring the use of oral antidiabetic agents or insulin

- History of eating disorders or other dietary patterns which are not consistent with the dietary intervention (e.g., vegetarians, very low fat diets, high protein diets)

- Use of prescription or over-the-counter antiobesity medications or supplements (e.g., phenylpropanalamine, ephedrine, caffeine) during and for at least 6 months prior to the start of the study or a history of a surgical intervention for obesity

- Active cardiovascular disease (such as a heart attack or procedure within the past three months or participation in a cardiac rehabilitation program within the last three months, stroke, or history/treatment for transient ischemic attacks in the past three months, or documented history of pulmonary embolus in the past six months).

- Use of any tobacco products in past 6 months

- Use of oral or IV antibiotics during the month preceding the study or during the study

- Unwillingness to abstain from vitamin, mineral, and herbal supplements for two weeks prior to the study and during the study

- Known (self-reported) allergy or adverse reaction to garlic

- Inability to metabolize garlic

- Unable or unwilling to give informed consent or communicate with study staff

- Self-report of alcohol or substance abuse within the past twelve months and/or current acute treatment or rehabilitation program for these problems (Long-term participation in Alcoholics Anonymous is not an exclusion)

- Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Control
Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume 270 kcal white bread with 15 g margarine.
Garlic treatment
Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume 270 kcal white bread with 15 g margarine and 5 g crushed garlic.

Locations

Country Name City State
United States USDA Beltsville Human Nutrition Research Center Beltsville Maryland

Sponsors (1)

Lead Sponsor Collaborator
USDA Beltsville Human Nutrition Research Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Garlic metabolites Garlic metabolites will be measured in blood and urine. Day 11 of each treatment period -- before and 3 hours after treatment
Primary Markers of gene expression Lymphocyte microarray analysis, lymphocyte DNA genotyping. Microarray results will be confirmed by RT-PCR. Day 11 of each treatment period -- before and 3 hours after treatment
Primary DNA damage Comet assay, 8-oxo-dG, histone analysis Day 11 of each treatment period -- before and 3 hours after treatment
Primary Oxidative stress Serum nitrate/nitrite, malondyaldehyde, glutathione, glutathione reductase, glutathione S-transferase, catalase, protein carbonyls, F2-isoprostanes. Day 11 of each treatment period -- before and 3 hours after treatment
Primary Biomarkers of inflammation C-reactive protein (CRP), vascular endothelial growth factor, IL-1, IL-6, TNF-a. Day 11 of each treatment period -- before and 3 hours after treatment
See also
  Status Clinical Trial Phase
Completed NCT02575209 - Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects N/A
Completed NCT00900107 - Time-Dependent Mobilization of Circulating Progenitor Cells During Strenuous Exercise in Healthy Individuals N/A
Completed NCT02517775 - Effects of Cranberry Consumption in Vascular Function in Healthy Individuals N/A
Active, not recruiting NCT03298373 - 28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men Phase 1
Completed NCT03339167 - Metabolic Availability of Lysine From Millet in Adult Men N/A
Completed NCT01710280 - Palmitic Acid in the Sn-2 Position of Triacylglycerols and Postprandial Lipemia N/A
Completed NCT01130948 - Sleep, Breathing and Psychomotor Performance at Altitude: A Physiologic Study in Healthy Subjects N/A
Completed NCT01382069 - Phase 1 Study of Dimethandrolone Undecanoate in Healthy Men Phase 1
Recruiting NCT05523674 - Effects of Warm-up Intensity and Blood Flow Restriction N/A
Not yet recruiting NCT05865574 - A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 Injection Phase 1
Completed NCT01296997 - Calcium Phosphate and Incretins N/A
Completed NCT00935662 - A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses Phase 1
Completed NCT01221558 - Effects of Lycopene on Oxidative Stress and Markers of Endothelial Function Healthy Men Phase 3
Active, not recruiting NCT05825781 - Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man Phase 1
Completed NCT02994602 - Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males Phase 1
Completed NCT02365987 - The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Lipaemia and Satiety N/A
Completed NCT02072278 - Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects Phase 1
Completed NCT02093169 - D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound Phase 1
Completed NCT03411005 - Metabolic Availability of Lysine From Sorghum in Adult Men N/A
Recruiting NCT02927210 - Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015) Phase 1